Sitewide SALE! GET 15% Off! Use Code EPX15 *
Flovent HFA is used to treat asthma and helps to prevent symptoms of asthma. Flovent HFA contains a medicine called fluticasone propionate, which is a synthetic corticosteriod. Corticosteroids are nautral substances found in the body to help fight inflammation. Flovent helps reduce airway inflammation, an underlying cause of asthma symptoms.
Flovent HFA (fluticasone) is an inhaled aerosol steroid that is proven effective in humans, as well as cats and dogs suffering from chronic asthma or bronchitis. Your veterinarian can choose from three different strengths of Flovent for your pet. A built-in dose counter on the canister makes it easy to track the number of doses left. Using special feline and canine aerosol masks (sold separately) helps ensure that your pet receives the full dose of Flovent.
Flovent helps reduce swelling and irritation in the airways of the lung so your dog or cat can breathe easier. The active ingredient in Flovent HFA (Fluticasone) is a corticosteroid that’s proven to reduce inflammation, a major cause of constricted, difficult breathing.
View Floven HFA Drug Facts Sheet.
FLOVENT HFA should be administered by the orally inhaled route only in patients aged 4 years and older. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis.
Individual patients will experience a variable time to onset and degree of symptom relief. Maximum benefit may not be achieved for 1 to 2 weeks or longer after starting treatment.
After asthma stability has been achieved, it is always desirable to titrate to the lowest effective dosage to reduce the possibility of side effects. For patients who do not respond adequately to the starting dosage after 2 weeks of therapy, higher dosages may provide additional asthma control. The safety and efficacy of FLOVENT HFA when administered in excess of recommended dosages have not been established.
The recommended starting dosage and the highest recommended dosage of FLOVENT HFA, based on prior asthma therapy, are listed in Table 1.
| Previous Therapy | Recommended Starting Dosage | Highest Recommended Dosage |
|---|---|---|
| Adult and adolescent patients (aged 12 yearsand older) | ||
| Bronchodilators alone | 88 mcg twice daily | 440 mcg twice daily |
| Inhaled corticosteroids | 88-220 mcg twice dailya | 440 mcg twice daily |
| Oral corticosteroidsb | 440 mcg twice daily | 880 mcg twice daily |
| Pediatric patients (aged 4-11 years)c | 88 mcg twice daily | 88 mcg twice daily |
a Starting dosages above 88 mcg twice daily may be considered for patients with poorer asthma control or those who have previously required doses of inhaled corticosteroids that are in the higher range for the specific agent.
b For patients currently receiving chronic oral corticosteroid therapy, prednisone should be reduced no faster than 2.5 to 5 mg/day on a weekly basis beginning after at least 1 week of therapy with FLOVENT HFA. Patients should be carefully monitored for signs of asthma instability, including serial objective measures of airflow, and for signs of adrenal insufficiency [see Warnings and Precautions (5.4)]. Once prednisone reduction is complete, the dosage of FLOVENT HFA should be reduced to the lowest effective dosage.
c Recommended pediatric dosage is 88 mcg twice daily regardless of prior therapy. A valved holding chamber and mask may be used to deliver FLOVENT HFA to young patients.
Prime FLOVENT HFA before using for the first time by releasing 4 sprays into the air away from the face, shaking well for 5 seconds before each spray. In cases where the inhaler has not been used for more than 7 days or when it has been dropped, prime the inhaler again by shaking well for 5 seconds and releasing 1 spray into the air away from the face.
Inhalation Aerosol. Dark orange plastic inhaler with a peach strapcap containing a pressurized metered-dose aerosol canister containing 120 metered inhalations and fitted with a counter. Each actuation delivers 44, 110, or 220 mcg of fluticasone propionate from the mouthpiece.
Keep out of reach of children and pets. Store at room temperature. Shake product well before use.
Most common adverse reactions (incidence greater than 3%) are upper respiratory tract infection or inflammation, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, and headache.
To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
FLOVENT HFA is a prescription inhaled corticosteroid (ICS) medicine for the long-term treatment of asthma in people aged 4 years and older.
Do not use FLOVENT HFA:
Tell your healthcare provider about all of your health conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FLOVENT HFA and certain other medicines may interact with each other. This may cause serious side effects. Especially, tell your healthcare provider if you takeantifungal or anti-HIV medicines.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Read the step-by-step instructions for using FLOVENT HFA at the end of this Patient Information.
FLOVENT HFA can cause serious side effects, including:
Tell your healthcare provider about any side effect that bothers you or that does not go away.
These are not all the side effects with FLOVENT HFA. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
